News
Appointments to the National Cancer Registry Board - 15 July 2021
From Department of Health
Published on
Last updated on
From Department of Health
Published on
Last updated on
Mary Bourke
Mary Bourke is a graduate of University College Cork where she majored in Microbiology and completed a Master of Analytical Chemistry degree. She also completed a Diploma in Pharmaceutical Manufacturing Technology in Trinity College Dublin. She has worked in the pharmaceutical industry in Ireland, the United States, Puerto Rico, Spain and Switzerland. She has worked with GlaxoSmithKline, Schering Plough, Novartis, Wyeth, AbbVie, Pfizer and Bristol Myers Squibb. Her expertise is in the area of Quality Assurance and Quality Control in drug substance and drug product manufacture of both small and large molecules. She has established and led quality departments and is very knowledgeable in regulatory inspections by health authorities globally. She recently led the Bristol Myers Squibb Global Risk Assessment programme for quality oversight of Contract Manufacturing Organizations. She has a unique breadth of experience through her leadership in quality assurance across organisations, geographies and regulatory authorities.
Mark Lawler
Mark is an internationally renowned scientist with over 200 papers including key publications in the highest impact journals. His work has been recognised by numerous national and international awards. He is Associate Director of Health Data Research Wales-Northern Ireland which is driving innovative precision medicine and public health approaches through the use of Big Data. He is Scientific Director of DATA-CAN, the UK’s National Health Data Research Hub for Cancer.
Mark has a strong commitment to patient-centred research/care and to addressing cancer inequalities. He was architect of the European Cancer Patient's Bill of Rights, which he launched in the European Parliament with colleagues on World Cancer Day 2014. The Bill of Rights received The 2018 European Health Award, a prestigious award for partnerships that yield real health impact in Europe. Mark’s work on addressing inequalities and access issues in relation to cancer care formed the center piece in the development by the European Cancer Organisation of the European Code of Cancer Practice, which Mark launched (virtually) with EU Health and Food Safety Commissioner Stella Kyriakides in Brussels in September 2020
Mark’s work on Covid-19 and its impact on cancer services and cancer patients has received international attention and he co-chairs the European Cancer Organisation’s (E.C.O) Special Focused Network on Covid-19 and cancer, which launched its 7-Point plan to Build Back Better (and smarter) from Covid. He presented recent data on Covid’s impact on cancer in Europe to the Europe Beating Cancer Committee in the European Parliament and launched E.C.Os pan European Time To Act Campaign to ensure that Covid-19 does not stop us from tackling cancer. This work recently received the prestigious Royal College of Physicians Excellence in Patient Care Award.
Mark recently received the Irish Association for Cancer Research’s Outstanding Contribution to cancer research award, for his pioneering work on cancer research and cancer care on the island of Ireland. Mark is Chair of the International Cancer Benchmarking Partnership, an international collaborative that employs a data- driven approach to improve outcomes for cancer patients.